OssDsign AB (publ) publishes Q2 2021 Interim Report

Continued sales growth despite ongoing COVID-19 pandemic

The second quarter in figures

• Net sales amounted to TSEK 7,643 (3,905)
• Loss after taxes amounted to TSEK 25,332 (22,586)
• Earnings per share was SEK -0.4 (-1.3)
• Cash flow from current operations was TSEK -11,169 (-15,829)

The first half year in figures

• Net sales amounted to TSEK 13,629 (11,631)
• Loss after taxes amounted to TSEK 48,661 (40,898)
• Earnings per share was SEK -1,2 (-2.3)
• Cash flow from current operations was TSEK -34,503 (-37,962)

Important Events during the second quarter

• OssDsign raised SEK 270 million in a 185% oversubscribed rights issue and utilised the over-allotment option of SEK 30 million.
• New scientific paper in Journal of Neurosurgery further confirms osteointegration of OssDsign Cranial PSI implants in humans, a clear differentiation from competitors.
• New preclinical trial data, published in The Spine Journal, shows that OssDsign's innovative synthetic bone graft OssDsign Catalyst outperforms a comparable device in bone formation following spinal fusion surgery.

Important Events after the end of the second quarter.

• OssDsign Catalyst now launched on the U.S. market.
• OssDsign enters into agreement with Premier Inc, a leading group purchasing organisation in the U.S. giving access to 4,100 hospitals.
• OssDsign partners with Red One Medical and enters into DAPA agreement to provide reconstructive cranial solutions and synthetic bone grafts to U.S. veterans and active military members.
• OssDsign selected to exhibit OssDsign Cranial PSI at Vizient Innovative Technology Exchange in the U.S..
• OssDsign’s Management and Board of Directors increase their long-term commitment through acquisition of warrants for a total amount of approximately SEK 1.3 million.

The Q2 2021 results will also be presented at an investor webcast today August 18th at 11:00 CET. The webcast can be accessed via the following link https://www.finwire.tv/webcast/ossdsign/q2-2021/  or via the OssDsign website.  


For further information, please contact:
 Morten Henneveld, CEO, OssDsign AB
Tel: +46 73 382 43 90, email: morten.henneveld@ossdsign.com

Certified Adviser:
Erik Penser Bank AB is the company’s Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: certifiedadviser@penser.se.

About OssDsign
OssDsign’s vision is to provide regenerative solutions to all patients with cranial or spinal bone defects, so they can be restored and healed as naturally as possible. Driven by a commitment to give patients back the lives they deserve, OssDsign collaborates with surgeons to engineer better healing by integrating biomaterials with clinical design. Headquartered in Sweden, OssDsign supplies hospitals worldwide with implants for use in cranial reconstructions and other orthopaedic surgery applications.

This information is information that OssDsign AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at 08:00 CET on August 18, 2021.
 

Tags: